touchSATELLITE SYMPOSIUM Latest developments in neuromyelitis optica spectrum disorder: Diagnostics, treatments and patient-centred care
Three experts examine evidence-based approaches for early and accurate diagnosis, appropriate treatment selection and patient-centred care to mitigate the clinical burden of neuromyelitis optica spectrum disorder.
Dr Dalia Rotstein
University of Toronto, ON, Canada
CHAIR
Panelists:
Dr Dalia Rotstein opens the symposium and sets the scene for discussions on the latest developments in the diagnosis, treatment and management of NMOSD.
Dr Eoin Flanagan discusses the characterization of NMOSD, and the latest evidence-based strategies to achieve timely and accurate diagnosis.
Dr Dalia Rotstein poses questions from the live audience at the Consortium of Multiple Sclerosis Centers Annual Meeting 2023 to Dr Eoin Flanagan. To view audience questions, please view the downloadable slides.
Dr Jeffrey Bennett reviews the latest efficacy and safety data on immunotherapies for NMOSD, and the factors influencing clinical decision making in daily practice.
Dr Dalia Rotstein poses questions from the live audience at the Consortium of Multiple Sclerosis Centers Annual Meeting 2023 to Dr Jeffrey Bennett. To view audience questions, please view the downloadable slides.
Dr Dalia Rotstein summarizes the wider clinical symptoms of NMOSD and multidisciplinary strategies to mitigate the burden of disease.
In this interactive session, the panellists answer questions from the live audience at the Consortium of Multiple Sclerosis Centers Annual Meeting 2023 and provide their expert insights on how multidisciplinary, patient-centred strategies can be implemented to manage the burden of symptoms of NMOSD. To view audience questions, please view the downloadable slides.
Overview & Learning Objectives
Overview
In this touchSATELLITE SYMPOSIUM activity, leading experts in neuromyelitis optica spectrum disorder (NMOSD) examine evidence-based approaches to achieve early and accurate diagnosis of NMOSD, leading to appropriate treatment selection. They explore the latest clinical data on current and emerging treatments, and discuss multidisciplinary strategies to mitigate the clinical burden of NMOSD and improve patient quality of life.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of neurologists, including neuroimmunologists; neuroradiologists; ophthalmologists, including neuro-ophthalmologists; and specialist neurology nurses involved in the management of NMOSD.
Disclosures
Faculty
Dr Dalia Rotstein discloses: Advisory board or panel fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi. Grants/research support from Roche. Speaker’s bureau fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis. Â
Dr Eoin Flanagan discloses: Advisory board or panel fees from Alexion, Genentech, Horizon Therapeutics and UCB (All relationships terminated). Grants/research support from UCB.  Â
Dr Jeffery Bennett discloses: Advisory board or panel fees from Clene Nanomedicine, Genentech and Roche. Consultancy fees from AbbVie (relationship terminated), Alexion Pharmaceuticals, Antigenomycs (relationship terminated), BeiGene, Chugai Pharmaceutical, Genentech, Genzyme (relationship terminated), Horizon Therapeutics, Imcyse, Mitsubishi Tanabe Pharma, Reistone Biopharma, Roche and TG Therapeutics. Grants/research support from Alexion, Mallinckrodt Pharmaceuticals and Novartis. Other financial or material support from Aquaporumab. Speaker’s bureau fees from Alexion.
Content reviewer
Niraja S Suresh has no interests/relationships or affiliations to disclose in relation to this activity.
Touch Medical Directors
Adriano Boasso and Aniket Parikh have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 22 June 2023. Date credits expire: 22 June 2024.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
Learning Objectives
After watching this activity, participants should be better able to:
- Recall strategies that facilitate an early and accurate diagnosis of NMOSD
- Describe how evidence from clinical trials investigating current and emerging treatments for NMOSD informs clinical decision making
- Select individualized management plans for patients with NMOSD to reduce the patient-reported burden of symptoms
Faculty & Disclosures
Dr Dalia Rotstein
University of Toronto, ON, Canada
Dr Dalia Rotstein is a neurologist at St. Michael’s Hospital and an assistant professor at the University of Toronto, ON, Canada. Her research is focused on the epidemiology of multiple sclerosis and other demyelinating diseases in diverse populations, with the goal of promoting more inclusive care and equitable outcomes. read more
Dr Rotstein has a particular interest in the roles of sex, ethnicity, migration and Epstein-Barr virus infection in these conditions. She is the principal investigator for CANOPTICS, the first Canadian national prospective study to investigate adults with neuromyelitis optica spectrum disorders, myelin oligodendrocyte glycoprotein antibody-associated disease and other atypical demyelinating conditions.
Dr Dalia Rotstein discloses: Advisory board or panel fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi. Grants/research support from Roche. Speaker’s bureau fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis. Â
Dr Eoin Flanagan
Mayo Clinic, Rochester, MN, USA
Dr Eoin Flanagan is a professor of neurology and consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic, Rochester, MN, USA. He completed his neurology residency and was awarded fellowships in neuroimmunology and a masters in clinical and translational science at the Mayo Clinic, Rochester. read more
Dr Flanagan works in the Center for Multiple Sclerosis and Autoimmune Neurology clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research are focused on myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders, transverse myelitis and other myelopathies, autoimmune encephalitis, paraneoplastic neurologic disorders and multiple sclerosis. He is a principal investigator on a National Institutes of Health research project grant studying MOGAD, and was a member of the International MOGAD panel that devised its diagnostic criteria.
Dr Eoin Flanagan discloses: Advisory board or panel fees from Alexion, Genentech, Horizon Therapeutics and UCB (All relationships terminated). Grants/research support from UCB.  Â
Dr Jeffrey Bennett
University of Colorado, Aurora, CO, USA
Dr Jeffrey Bennett is the Gertrude Gilden professor for neurodegenerative disease research in the departments of Neurology and Ophthalmology at the University of Colorado (CU) School of Medicine, Aurora, CO, USA. He is also a faculty member of the programmes in immunology and neuroscience, and the Rocky Mountain MS Center at Anschutz Medical Campus, Aurora. read more
Dr Bennett directs basic, translational and clinical research programmes on neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), optic neuritis and myelin oligodendrocyte glycoprotein antibody-associated disease, and maintains active specialty practices in neuro-ophthalmology and neuroimmunology. He has received the Stephen Reingold Award from the National MS Society and the CU Experts Inventor of the Year Award.
Dr Bennett has been a leader in understanding the role of B cells in demyelinating disorders. Using single cell recombinant monoclonal antibody technology, his laboratory has probed the targets of the immune response in NMOSD and MS. His research in NMOSD has elucidated the pathogenicity of aquaporin-4 (AQP4) autoantibodies, identified B cell epitopes on AQP4 protein, and assisted in the development of novel antigen-specific therapies. He is widely published, and is a regular member of scientific review committees for the National Institutes of Health and the National MS Society.
Dr Jeffery Bennett discloses: Advisory board or panel fees from Clene Nanomedicine, Genentech and Roche. Consultancy fees from AbbVie (relationship terminated), Alexion Pharmaceuticals, Antigenomycs (relationship terminated), BeiGene, Chugai Pharmaceutical, Genentech, Genzyme (relationship terminated), Horizon Therapeutics, Imcyse, Mitsubishi Tanabe Pharma, Reistone Biopharma, Roche and TG Therapeutics. Grants/research support from Alexion, Mallinckrodt Pharmaceuticals and Novartis. Other financial or material support from Aquaporumab. Speaker’s bureau fees from Alexion. Â
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 8 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
